Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis [1]

Archives of Dermatology

Volumn 143, Issue 5, 2007, Pages 659-661

  Demierre, Marie France ^a   Ferzli, Pascal ^b   Miller, Donald ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; METHOXSALEN;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DEMOGRAPHY; DISEASE SEVERITY; EMOTIONALITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFORMED CONSENT; LETTER; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEZARY SYNDROME; SOCIAL ASPECT; VARIANCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICARCINOGENIC AGENTS; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOPHERESIS; PILOT PROJECTS; QUALITY OF LIFE; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 34249090183     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.5.659     Document Type: Letter

References (9)

1. Demierre MF, Tien A, Miller DR. Health related quality of life assessment in patients with cutaneous t-cell lymphoma. Arch Dermatol. 2005;141:325-330.
2. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433-1440.
3. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
4. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388.
5. Demierre MF, Vachon L, Ho V, Sutton L, Cato A, Leyland-Jones B. Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides. Arch Dermatol. 2003;139:624-628.
6. Zackheim HS, Koh HK, Weinstock MA. Assessing clinical outcomes in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:1021-1029.
7. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003;17:1485-1507.
8. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56:52-60.
9. Chren MM. Measurement of vital signs for skin diseases. J Invest Dermatol. 2005;125:viii-ix.